Navigation Links
Androgen receptor may explain male dominance in liver cancer
Date:5/19/2010

od, namely that men with HBV are much more likely to develop cancer than women with the same infection," said Aram Hezel, M.D., a gastrointestinal oncologist at the James P. Wilmot Cancer Center at University of Rochester Medical Center. "This is great use of the tools of genetics and mouse modeling to explain a clinical finding and most importantly turn our attention to potentially more promising treatment approaches for patients with hepatocellular carcinoma."

"This study also raises the possibility of prevention among men with HBV infection through inhibition of the androgen receptor," Hezel added. "The potential impact on clinical care is great."

For decades Chang has focused on the particular role of the AR in human health. In 1988 he successfully cloned AR, which led to breakthroughs in several AR-related diseases such as prostate and bladder cancer, and Kennedy's neuron disease, a rare and progressive motor disorder similar to Lou Gehrig's disease, and that affects only men.

The AR is central to the action of testosterone and has a profound effect on many organs. In previous experiments, Chang has shown that mice without AR have dramatically lower rates of bladder cancer, a cancer that strikes men three times more often than women.

Male dominance in liver cancer suggested that the AR would be a key factor, as well. (About 74 percent of liver cancer cases occur in men.) Chang's objective was to locate a new pathway for treatment that would not require depletion of androgen levels in the entire body, which amounts to castration and causes severe side effects for patients.

His study took the first step toward demonstrating this could be done, at least for early stage liver cancer. Researchers showed that an experimental drug, ASC-J9, attacked and degraded the faulty AR, and suppressed liver tumors in mice.

Chang developed ASC-J9 earlier this decade and first reported on its clinical potential in March 2007
'/>"/>

Contact: Leslie Orr
Leslie_Orr@urmc.rochester.edu
585-275-5774
University of Rochester Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Intermittent androgen deprivation at least as effective as continuous androgen deprivation
2. Brain dopamine receptor density correlates with social status
3. Pharmacokinetic/Pharmacodynamic Data Support Further Development of Tobiras Next-Generation CCR5 Receptor Antagonist
4. New Guidelines Issued on Hormone Receptor Testing for Breast Cancer
5. Cell study finds receptor can fight tamoxifen-resistant breast cancer cells
6. Estrogen receptor status of HER2+ breast cancer correlates with response to anti-HER therapies
7. Scientist Who Helps Explain Pain Wins Grawemeyer Award
8. Study explains why light worsens migraine headaches
9. Three Anticoagulant Studies May Change Current Medical Practice Including New Data Revealing That Preventative Use of Aspirin and Heparin is Not Effective in Reducing Recurrent, Unexplained Miscarriages
10. Fish Oil Explained Thanks To Unveiling of New Website “fishoil.com”
11. Personal Injury Attorney David Perecman Explains the Possible Legal Consequences of Fatal 911 Operator Error in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 18, 2013 Although obesity is associated ... association between obesity and esophageal adenocarcinoma, a type of ... tumors. As reported on Cancer.gov, last reviewed ... twice as likely as those of normal and healthy ... between obesity and esophageal cancer is not well understood, ...
(Date:5/18/2013)... Show And Go Training, the culmination of ... systems that is all about is getting results in the ... http://ShowAndGoTrainingReview.com ’s Stan Stevenson, prompting an investigative review. ... “four phase system” designed to make you faster, stronger, fitter ... working out in the gym. The training manual and exercise ...
(Date:5/18/2013)... 18, 2013 Losing weight remains to be ... the horde of new weight loss products available in the ... Recent studies about this newest weight loss supplement prove that ... shape. , Garcinia Cambogia is a sub-tropical fruit that is ... the fruit can suppress a person’s appetite, while it effectively ...
(Date:5/18/2013)... 2013 John Ravera, D.D.S., a Newport ... a new member to his dental team, Courtney Marino. , ... field for over 10 years. She received her degree from ... elected a member of Sigma Pi Alpha, a national honor ... working with patients of all ages, helping them understand the ...
(Date:5/18/2013)... Medical device company, FlexLeg, LLC, last week began taking reservations ... its namesake, the FlexLeg. The device uses technology from ... injured individuals can use to walk on various terrains. Those ... walk during a typical 6-8 week recovery period , FlexLeg’s ... who need the device most are able to reserve one ...
Breaking Medicine News(10 mins):Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 2Health News:hCGtreatments / Diet Doc Hcg Diets & Weight Loss Plans Announces New Prescription Hcg Diet Plans Designed to Trim Inches and Thus Reduce the Risk of Esophageal Cancer 3Health News:Show And Go Training: Review Examining Eric Cressy's Workout Program Revealed 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2Health News:FlexLeg Begins Offering New Mobility Aid 2
... Feb. 10 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. ... 9, 2009, following a bench trial, the district court entered ... Par in the amount of $69,955,476. As a result ... approximately $28 million on an after-tax basis in the fourth ...
... suite includes one-of-a-kind claims processing, business intelligence, ... truly compete in the 21st-century healthcare marketplaceBURLINGTON, ... the only modern, enterprise-class software platform for ... Services has selected the HealthRules product suite ...
... 10 SurgiQuest, Inc. AirSeal Dynamic Pressure System(TM) ... The AirSeal DPS(TM) continuously re-circulates and filters CO2 ... procedures.Surgeons routinely have to interrupt laparoscopic surgical procedures ... and plume within the operative environment. This impairment ...
... with a range of uptime and virtualization solutionsMAYNARD, ... that it is partnering with Massachusetts-based Infinity Healthcare ... products for uptime reliability as part of its ... services provider specializing in systems integration, software development, ...
... HMS (Nasdaq: HMSY ) today announced that ... Health Providers and Optima Health, a Sentara service -- ... portfolio. HMS will provide these services to Neighborhood Health ... Plan in Virginia.HMS will identify health insurance coverage not ...
... Zeus, Inc. is pleased to introduce its ... and accessible via http://www.zeusinc.com .With innovative graphics ... resource for comprehensive information about Zeus products and ... organizes an extensive amount of information into four ...
Cached Medicine News:Health News:Par Pharmaceutical Announces Outcome of the Litigation With Pentech Pharmaceuticals 2Health News:Mississippi Administrative Services Chooses the HealthRules(R) Product Suite from HealthEdge(R) to Address Next-Generation Business Needs 2Health News:SurgiQuest Announces FDA Approval for Smoke & Plume Evacuation for AirSeal Dynamic Pressure System(TM) 2Health News:Stratus Technologies Partners With Infinity Healthcare Solutions to Resell Availability Products With Its Services 2Health News:Stratus Technologies Partners With Infinity Healthcare Solutions to Resell Availability Products With Its Services 3Health News:HMS Awarded New Contracts for Managed Care Services 2
(Date:5/17/2013)...  Boehringer Ingelheim will contribute to advancing the ... Thoracic Society International Conference (ATS 2013) in ... 22. Data will highlight research conducted ... chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® (tiotropium ... for asthma, idiopathic pulmonary fibrosis (IPF) and COPD. ...
(Date:5/17/2013)... May 17, 2013  Sanofi (EURONEXT: SAN and NYSE: ... JAKARTA , examining the selective JAK2 ... in both dose groups. The primary endpoint assessed the ... Consistent with data reported in previous trials, the most ... Full results will be presented at an upcoming medical ...
(Date:5/17/2013)... , May 17, 2013  Boston Scientific Corporation ... at the annual EuroPCR Scientific Program May 21-24 in ... pleased to present a particularly rich and diversified set ... Keith Dawkins , M.D., global chief medical officer, ... will be presented, including the NG PROMUS trial, which ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8
... Calif., March 15, 2011 XTIO2 INC ... -nominees with the XTI ANTI-GERM / ANTI-VOC / ... and XTI™  Nano-Facemask . It is the ... against germs transmitted via air and contact surfaces. The ...
... FRANCISCO, March 15, 2011 Motion Therapeutics, Inc. ... for balance and mobility disorders, today announced that researchers ... a NIH Recovery Act Grant to study the effects ... and mobility in people with MS. ...
Cached Medicine Technology:OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 2OSCAR® Nominees Receive (XTIO2 INC.) XTI 360™ Nano Coating Anti-Germ System 3The Balance-Based Torso-Weighting® Treatment for Multiple Sclerosis Receives a NIH Recovery Act Grant 2
Provides a combination of concentrated cold / hot and compression for the neck...
Provides a combination of concentrated cold / hot and compression for the back...
... One-Piece™ Collar is completely injected molded from ... our patented chin support. , ,Our ... efficiently managed where space is limited. Color-coded ... of sizes., ,Either in a supine ...
... optional hot and cold therapy Gel Pad. Our ... providing cold therapy to reduce swelling and /or ... recovery., ,To order hot and cold therapy ... number., ,Our suspenders can be added to ...
Medicine Products: